Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (> 50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1–21 or days 1–7 and 15–21, repeated every 28 days (4 treatment regimens). Responses were seen i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Main Authors: Erba, Harry P., Othus, Megan, Walter, Roland B., Kirschbaum, Mark H., Tallman, Martin S., Larson, Richard A., Slovak, Marilyn L., Kopecky, Kenneth J., Gundacker, Holly M., Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247790/
https://ncbi.nlm.nih.gov/pubmed/24411921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.12.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados